PCCA's Clinical Services team is populated with hard-working, dedicated pharmacy professionals who strive each day to make a difference in pharmacy compounding. As a team, they act as a cornerstone of PCCA's abiding desire to provide pharmacies with answers to tough questions. The Clinical Services Spotlight is a limited series of articles designed to highlight a singular member of the Clinical Services team. This article focuses on Matt Martin, PharmD, a man destined to wear PCCA blue.

PCCA's Matt Martin and Melissa Merrell Rhoads provide an update on the FDA's decision to designate human chorionic gonadotropin (HCG) as a biologic product and what that means for compounders and for PCCA.

The only thing that stays the same is that everything changes. This is true even when it comes to nonsterile compounding and USP <795>. PCCA Clinical Compounding Pharmacist Matt Martin, PharmD, addresses notable changes of the new USP guidelines and provides some considerations regarding implementation.

"Do you have questions about what it means to be compliant with various parts of USP <800>?" "Do you have the equipment you need?" Matt Martin, PharmD, of PCCA's Clinical Services provides an in-depth checklist of considerations you need to have while trying to navigate USP <800>.

PCCA's VP of Clinical Services A.J. Day and Matt Martin, PCCA Clinical Compounding Pharmacist, discuss how to navigate compounding with bulk drug substances while remaining within the FDA's guidelines.